ARTBIO

Amidst a rapidly evolving landscape, there has been increased attention on the benefits of #lead212 based radiopharmaceuticals vs other alpha-emitting radioisotopes. Three recent articles by Aayushi Pratap of C&EN and Karen Tkach Tuzman at BioCentury Inc. highlight the growing interest in lead-212 vs actinium-225, citing benefits such as ease of production, abundance of raw materials, potential for improved efficacy, and minimizing off-target effects for a potentially improved safety profile.   We are grateful to the authors for thoughtfully listening to and quoting ARTBIO’s CEO, Emanuele Ostuni, and for detailing the sector in such a comprehensive and inclusive way.  The articles effectively highlight the healthy debate surrounding the best methods to deliver therapies safely to patients. All companies in this space share a sharp focus on combining differentiated pipelines with state-of-the-art manufacturing, and we are confident that there will be many more future developments as each company continues to learn from their respective approaches.   ARTBIO’s proprietary AlphaDirectTM technology and distributed manufacturing approach help address the needs of a robust supply chain that matches lead-212’s shorter half-life – one of its key attributes.    ARTBIO is dedicated to building a unique #ART ecosystem that maximizes patient access, mitigates the shortcomings of centralized manufacturing approaches, and empowers patient-centric advances to redefine cancer care.   Read the C&EN article here: https://lnkd.in/eSJPySNa   Read the BioCentury articles here: https://lnkd.in/eRVfkUW9   https://lnkd.in/en_FS47C   Learn more about ARTBIO’s novel approach at: https://artbio.com/   #lead212 #alpharadioligandtherapy #radioligandtherapy

The month of June is rich in days dedicated to a variety of individual groups and activities, and as it comes to an end, we reflect on the abundant diversity we’ve honored. It’s been an incredible time of solidarity and pride, as we celebrated both #PrideMonth and #Juneteenth. We stand in unity with the LGBTQ and Black communities as we advocate for equality and inclusivity, both within our company and the world around us. We also recognize the courage and strength of cancer survivors in honor of #NationalCancerSurvivorsDay earlier this month. Your stories of resilience inspire us every day as we work to turn cancer into a more manageable disease. Realizing the ambitious vision of improving the lives of #cancer patients is a team effort, and our team’s strength comes from its diversity.    We remain dedicated to empowering all our current and future colleagues, and we believe that by embracing and celebrating our differences, we foster a stronger, more innovative ARTBIO.    Please follow us and join our team if you share our vision: https://lnkd.in/eCduHRpX

Two thoughtful articles on the #radiopharmaceutical space written by Melanie Senior and Rachel Nuwer of Nature Magazine Biotechnology. They highlight the growing interest of pharma companies and investors in #radioligand #therapy, while also exploring critical industry challenges. These include the need for reliable, high-quality supplies of medical isotopes and the identification of new targets across more tumor indications. Additionally, emerging pre-clinical and clinical data for both Pb212 and Ac225 show improved patient survival rates and effective targeting of low-expression cancer cells, particularly when radioactive isotopes are combined with checkpoint inhibitors. These takeaways echo many of the themes and discussions we heard at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) congress in Toronto. The alpha precursor #Pb212 is poised to be a game-changer in terms of efficacy and patient safety, with ARTBIO’s proprietary technology facilitating its supply and manufacturing routes. With few novel radiopharma targets available, our innovative approach to #alpha radioligand therapy (ART) development stands out and overcomes the challenges of existing #RLTs. Read the Nature articles here: https://lnkd.in/ep_Na-ma and https://lnkd.in/efiKbxgJ Learn more about ARTBIO’s novel approach at www.artbio.com #nuclearmedicine #biotech

This piece by Ned Pagliarulo in BioPharma Dive is a great primer on our recently announced collaboration with ARTBIO and the excitement surrounding #radiopharmaceuticals overall. As Ned writes, “The radiopharma field is booming, drawing substantial investment from large companies and venture capital firms eager to capitalize on the drugs’ potential to balance cancer-killing potency with better safety.” The Helicon-enabled radioligand therapies we will co-develop will benefit from the hyper-tunability of Helicons, to control the drugs’ distribution and half-life, and from the uniqueness of lead-212, one of the most promising isotopes for radiopharmaceutical use. Check out this photo of our teams together kicking off our partnership, and read the story here: https://bit.ly/3KN2zm5 #radioligandtherapy #cancer #oncology #peptides #Helicons #patients  

Our CEO Emanuele Ostuni is participating in a fireside chat today at the 2nd Annual TD Cowen Radiopharmaceutical Innovation Summit, where he will share ARTBIO’s latest news and shine a spotlight on our end-to-end approach to building a #manufacturing network and further developing our pipeline. More information on how ARTBIO is advancing #radiopharmaceutical development through our unique approach to #alpha #radioligand #therapy (ART) can be explored on our website: https://artbio.com/#about #RLT #biotech #Pb212

The ARTBIO team is excited to be attending this year‘s Society of Nuclear Medicine and Molecular Imaging (SNMMI) congress in Toronto. Kicking it off with the yearly 5k run - we look forward to connect, discuss and learn how to advance #alpha #radioligand #therapies together. #nuclearmedicine #radiopharmaceuticals

Today we strengthen our partnership with Oslo University Hospital and the Radiation Biology Institute, through a collaboration aimed at enhancing the mechanistic understanding of #Pb212-based #radiopharmaceuticals. This partnership expands our existing support of two graduate students for their PhD research.   This partnership will be enabled by our collective expertise to advance the research and development of #alpha #radioligandtherapy (#ART) in #cancer treatment. We are very excited to move the field forward through crucial research and development. Read more here: https://lnkd.in/ggBAwiF8 #RLT #prostatecancer #nuclearmedicine #biotech 

Earlier this week, Nuclear Medicine Europe, the European Industry Association for Nuclear Medicine, held their yearly general assembly, at which Daniel Rossetto introduced ARTBIO as a new member. ARTBIO is proud to partner with Nuclear Medicine Europe to raise awareness and advance #nuclearmedicine in the region. We are committed to redefining cancer care as we develop a new class of #alpha #radioligand therapies as well as their ecosystem that maximizes their potential. #Pb212 #radioligandtherapy #RLT #biotech #ART

ARTBIO Chief Scientific Officer Nick Pullen will be attending the 2nd Annual Boston Radionuclide Theranostics Forum tomorrow hosted by our partner Eckert & Ziegler SE at Morrison Foerster in Boston, MA. This forum will bring together leading experts in the field of #radiotheranostics and will build on the momentum of recent developments and approvals in the #radionuclide space. If you’re attending, connect with Nick to learn about how ARTBIO is offering a promising new approach to #cancer treatment with our #alpha #radioligand therapies. #RadionuclideTheranostics #Pb212 #radioligandtherapy #RLT #biotech

We have a position open in the Early Discovery team at ARTBIO, Cambridge. This is a great opportunity to join the Radioligand Therapy field. Please feel free to reach out if you are interested.